Dickson Medical Associates will pay $500,000 in civil damages for distributing non-FDA approved drugs.
The U.S. Attorney for the Middle District of Tennessee alleges that a physician at Dickson Medical Associates obtained and prescribed non-FDA approved Aclasta from foreign sources and billed for it as Reclast, which is approved in the United States. The drugs are used to treat osteoporosis and bone damage.
"The Food, Drug and Cosmetic Act and its enacting regulations exist to ensure the safety and efficacy of prescription drugs sold within the United States," David Rivera, U.S. Attorney, said in a release. "The resolution set fourth in this settlement agreement should send a clear message that this office will diligently pursue any violations of those laws."
In this month's Nashville Medical News, Dickinson Wright attorney Keith Dennen (pictured here) writes on the M&A regulatory climate in health care, specifically former Attorney General Bob Cooper's decision to join in an appellate court opinion brief on an Idaho antitrust suit. That, Dennen says, sets the stage very nicely for Cooper's successor, Herbert Slatery. The state's hospital operators and doctors are keenly watching and listening.
So the questions moving forward become — will Attorney General Slatery feel as strongly as his predecessor did about the monopolization of medicine? Will each and every future merger and collaborative effort be met with sharp scrutiny? Can we expect new legislation to emerge through the General Assembly, and will our struggling rural hospitals and smaller practitioners find that they need to source new ways of collaboration outside of an outright sale?
POSTDATA: WARRANTY DEEDS